ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Insmed Incorporated (INSM) Report Updated: Jun 21, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Insmed Incorporated (INSM)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: FPRX,AVXL,EXEL,ATHX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

Insmed Incorporated© quotemedia

Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers an anti-infective directly to the site of serious lung infections. The company’s ARIKAYCE is in Phase III clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. It also focuses on the development of INS1009, an inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension. Insmed Incorporated was founded in 1999 and is headquartered in Bridgewater, New Jersey.